세계의 흉막질환 시장 보고서(2025년)
Pleural Diseases Global Market Report 2025
상품코드 : 1730991
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 흉막질환 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 중 성장 원동력은 흉막질환 유병률 증가, 고령화 인구 증가, 직업적 위험 증가, 임상시험 증가, 진단센터의 확대 등이 예상됩니다.

감염의 유행 증가는 앞으로 몇 년 동안 흉막질환 시장의 성장을 이끌 것으로 예측됩니다. 예를 들어, 2023년 1월, 국립 의학 도서관은 감염이 연간 5,200만 명 이상의 사망의 원인이 되고 있으며, 세계 인구의 절반이 위험에 처해 있다고 보고하고 있습니다.

흉막질환 시장의 기업은 즉시 사용할 수 있는 주사 치료제의 개발에 주력하고 있습니다. 미국의 제약회사 Amneal Pharmaceuticals는 2024년 4월 첫 주사용 페메트렉세드의 ready-to-use 버전인 PEMRYDI RTU를 출시했습니다. 이 기술 혁신은 악성 흉막 중피종과 같은 흉막질환에 대한 재구성의 필요성을 없애고 준비 시간을 단축하고 투여 실수를 최소화하고 효과적인 치료에 대한 액세스를 개선함으로써 편리한 치료를 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Pleural diseases refer to a group of conditions that affect the pleura, the double-layered membrane surrounding the lungs. These diseases can involve inflammation, infection, or other pathological changes to the pleura. Symptoms of pleural diseases include chest pain, shortness of breath, coughing, and difficulty breathing, and they are often diagnosed using imaging tests such as chest X-rays or CT scans.

The primary types of pleural diseases include pleurisy, pleural effusion, pneumothorax, mesothelioma, and others. Pleurisy, which involves inflammation of the pleura, causes sharp chest pain and is often linked to infections or autoimmune disorders. Treatment options for pleurisy and other pleural diseases include medications, thoracentesis, pleurodesis, minimally invasive procedures, and surgical interventions. Diagnostic methods include imaging techniques, molecular diagnostics, thoracoscopy, and pleuroscopy. These services are commonly provided in hospitals, clinics, diagnostic centers, and research or academic institutions.

The pleural diseases market research report is one of a series of new reports from The Business Research Company that provides pleural diseases market statistics, including the pleural diseases industry's global market size, regional shares, competitors with a pleural diseases market share, detailed pleural diseases market segments, market trends and opportunities, and any further data you may need to thrive in the pleural diseases industry. This pleural diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pleural diseases market size has grown strongly in recent years. It will grow from $4.86 billion in 2024 to $5.23 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth observed during the historical period can be attributed to factors such as the rising incidence of pleural effusion, increasing awareness of pleural diseases, a growing focus on early diagnosis, the expanding number of healthcare facilities, and a rise in pleural disease clinical trials.

The pleural diseases market size is expected to see strong growth in the next few years. It will grow to $6.94 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period is expected to be driven by the increasing prevalence of pleural diseases, the rise in the aging population, a growing number of occupational hazards, an increase in clinical trials, and the expansion of diagnostic centers. Key trends for the forecast period include advancements in diagnostics and diagnostic tools, the adoption of minimally invasive procedures, improved drug development, and the growing adoption of telemedicine.

The rising prevalence of infectious diseases is expected to drive the growth of the pleural diseases market in the coming years. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, are becoming more widespread due to environmental changes, shifts in human behavior, and advancements in global travel. Conditions such as bacterial pneumonia, tuberculosis, or viral infections can lead to pleural disease by causing inflammation, infection, or fluid buildup in the pleural cavity. For example, in January 2023, the National Library of Medicine reported that infectious diseases are responsible for over 52 million deaths annually, putting half of the global population at risk. Furthermore, approximately 14 million children under the age of five die each year, with 70% of these deaths attributed to diseases that could be prevented through vaccination. As the prevalence of infectious diseases increases, it is driving the demand for treatments related to pleural diseases.

Companies in the pleural diseases market are focusing on developing ready-to-use injectable treatments. These pre-formulated and pre-diluted medications require no mixing or reconstitution before administration, ensuring convenience, accuracy, and reduced preparation time. For instance, in April 2024, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched PEMRYDI RTU, the first ready-to-use version of pemetrexed for injection. This innovation provides a convenient treatment for pleural diseases, such as malignant pleural mesothelioma, by eliminating the need for reconstitution, reducing preparation time, minimizing dosing errors, and improving access to effective therapy.

In October 2023, Aileron Therapeutics, a US-based biopharmaceutical company, acquired Lung Therapeutics for an undisclosed amount. This acquisition enhances Aileron's pipeline with LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusions (LPEs), further strengthening its focus on orphan pulmonary and fibrosis diseases. Lung Therapeutics, also based in the US, is known for developing innovative peptide drugs targeting fibrosis and rare pulmonary conditions.

Major players in the pleural diseases market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, GSK plc, Astrazeneca plc, Koninklijke Philips N.V., Becton Dickinson and Company, Boehringer Ingelheim International GmbH, Sanofi SA, Penn Medicine, Henry Ford Health, Dragerwerk AG, Emory Healthcare, Boston Medical Center, Cook Medical, WakeMed, Weill Cornell Medicine, Fox Chase Cancer Center, B. Braun SE, Bicakcilar, Redax S.p.a, Rocket Medical.

North America was the largest region in the pleural diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pleural diseases report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pleural diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pleural diseases market consist of revenues earned by entities by providing services such as diagnostic, pleurodesis, respiratory therapy, rehabilitation, and biopsy procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The pleural diseases market also includes sales of antibiotics, chemotherapeutic agents, thoracentesis kits, chest tubes and drainage systems, and pleural biopsy needles. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pleural Diseases Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pleural diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pleural diseases ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pleural diseases market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Pleural Diseases Market Characteristics

3. Pleural Diseases Market Trends And Strategies

4. Pleural Diseases Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pleural Diseases Growth Analysis And Strategic Analysis Framework

6. Pleural Diseases Market Segmentation

7. Pleural Diseases Market Regional And Country Analysis

8. Asia-Pacific Pleural Diseases Market

9. China Pleural Diseases Market

10. India Pleural Diseases Market

11. Japan Pleural Diseases Market

12. Australia Pleural Diseases Market

13. Indonesia Pleural Diseases Market

14. South Korea Pleural Diseases Market

15. Western Europe Pleural Diseases Market

16. UK Pleural Diseases Market

17. Germany Pleural Diseases Market

18. France Pleural Diseases Market

19. Italy Pleural Diseases Market

20. Spain Pleural Diseases Market

21. Eastern Europe Pleural Diseases Market

22. Russia Pleural Diseases Market

23. North America Pleural Diseases Market

24. USA Pleural Diseases Market

25. Canada Pleural Diseases Market

26. South America Pleural Diseases Market

27. Brazil Pleural Diseases Market

28. Middle East Pleural Diseases Market

29. Africa Pleural Diseases Market

30. Pleural Diseases Market Competitive Landscape And Company Profiles

31. Pleural Diseases Market Other Major And Innovative Companies

32. Global Pleural Diseases Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pleural Diseases Market

34. Recent Developments In The Pleural Diseases Market

35. Pleural Diseases Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기